Peptides > CJC-1295 DAC​

CJC-1295 DAC​

CJC-1295 is a lab-created version of growth hormone releasing hormone (GHRH), designed to enhance levels of growth hormone and insulin-like growth factor 1 (IGF-1) in the bloodstream. The addition of DAC, or drug affinity complex, serves to extend the duration of CJC-1295’s effectiveness in the body.

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.


1. CJC-1295-DAC Introduction


2. CJC-1295 Vs CJC-1295-DAC​


3. CJC-1295-DAC Structure


4. CJC-1295 Research


Growth hormone releasing hormone (GHRH) has undergone various modifications to create analogues that retain certain hormone effects while discarding others. Among these adaptations is CJC-1295, composed of the initial 29 amino acids of GHRH. This derivative, technically a maleimido derivative of hGRF(1-29), was developed with the goal of producing a more soluble GH secretagogue that can be manufactured in larger quantities while maintaining the physiological functions of GHRH.

CJC-1295 Vs CJC-1295 DAC

CJC-1295 is a modified version of the first 29 amino acids found in GHRH, making it chemically akin to other GHRH analogues such as Sermorelin. It shares the closest resemblance to modified GRF (1-29), although the two peptides are not identical. Confusion often arises due to these similarities, compounded by the fact that CJC-1295 was originally developed with the inclusion of a chemical component known as the drug affinity complex (DAC).

DAC is incorporated into the molecule using a lysine linker, serving to safeguard the peptide while it circulates within the bloodstream. By facilitating the binding of peptides to the common blood protein albumin, DAC significantly prolongs the half-life of CJC-1295 compared to similar molecules like GRF (1-29).


In its initial stages, ConjuChem Biotechnologies, the creator of DAC, originally named the molecule containing DAC as CJC-1295. However, this led to confusion as the peptide was also available without DAC. To mitigate this confusion, the version of CJC-1295 that includes DAC is now referred to as CJC-1295-DAC, while the variant without DAC is known as CJC-1295 or CJC-1295-no DAC.

CJC-1295-DAC Structure

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.954 g/mol
PubChem CID: 56841945

Source: PubMed

CJC-1295-DAC Research

Enhancing Growth Hormone Levels: CJC-1295, as a derivative of GHRH, effectively stimulates the release of growth hormone (GH) in the body. Research demonstrates that a single dose of CJC-1295 can lead to a remarkable 2-10 times increase in GH levels in mice. This elevation in GH concentration typically reaches its peak around 2 hours post-administration and continues to exert its effects for approximately six days.

Preservation of Normal GH Release: A distinguishing feature of CJC-1295 is its ability to maintain the natural, physiologic release of GH. This means that it does not disrupt the normal circadian rhythm of GH secretion, allowing for a more balanced and physiologically consistent GH release pattern. This property aligns CJC-1295 with the characteristics of a physiologic growth hormone releasing factor.

Impact on Growth and Development: Studies conducted in mice lacking normal GHRH physiology have underscored CJC-1295’s potential to preserve regular GH release. This suggests that CJC-1295 could be beneficial in addressing issues related to abnormal growth, both in mice and potentially in humans. The maintenance of normal pulsatile GH release is crucial for ensuring the proper release of downstream hormones, particularly insulin-like growth factor-1 (IGF-1).

CJC-1295 and Its Role in Addressing Infertility

Promoting Ovulation: Research dating back to the early 1990s indicates that CJC-1295 and other analogs of GHRH may have applications in promoting ovulation among infertile female patients. It is well-established that ovulation is influenced by factors like IGF-1 and GH release. Animal studies have supported these concepts, demonstrating that GH and IGF-1 levels rise significantly during ovulation. Exogenous administration of GH secretagogues, including CJC-1295, has shown the potential to induce proper ovulation.

Exploring Male Infertility: While the impact of CJC-1295 on female infertility and ovulation is becoming clearer, there is also speculation that this peptide and similar analogs might hold promise in addressing male infertility by potentially regulating sperm production. However, further research is needed to investigate this hypothesis fully.

The multifaceted effects of CJC-1295 make it a subject of interest in various areas of research, offering potential insights into growth regulation, reproductive health, and more.

CJC-1295 Summary

CJC-1295 is a growth hormone secretagogue designed to have a long plasma half-life and to preserve the physiologic patterns inherent in the GH axis. On both accounts, the molecule has been a success. CJC-1295 has experienced limited interest in research settings due to the advent of a number of similar molecules and because of the proprietary nature of the molecule’s structure. Now that CJC-1295 can be manufactured at will, there is likely to be renewed interest in its properties, particularly as they apply to the increasingly frustrating problem of human infertility.

CJC-1295 exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. CJC-1295 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy CJC-1295 if you are a licensed researcher.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.